Cancer Cell Signaling
Cancer Cell Signaling - Related Videos
10:13
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
0 Views •
Cited by 6 •
2013
Achieving a systems level understanding of cellular processes is a goal of modern-day cell biology. We describe here strategies for multiplexing luciferase reporters of various cellular function end-points to interrogate gene function using genome-scale RNAi libraries.
16:24
Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
0 Views •
Cited by 9 •
2014
Molecular signaling through both estrogen and microRNAs are critical in breast cancer development and growth. Estrogen activates the estrogen receptors, which are transcription factors. Many transcription factors can regulate the expression of microRNAs, and estrogen-regulated microRNAs can be profiled using different large-scale techniques.
15:53
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
0 Views •
Cited by 13 •
2013
The cytotoxic activity of the phenanthridine PJ-34 in cancer cells undergoing mitosis was documented in real time by live confocal imaging. PJ-34 eradicated human breast cancer MDA-MB-231 cells harboring extra-centrosomes in mitosis. Unlike normal bi-focal mitosis, the extra-centrosomes were not clustered in the two spindle poles in the presence of PJ-34.
03:03
mTOR Signaling and Cancer Progression
0 Views •
2023
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors. The mTOR pathway or the...
03:03
mTOR Signaling and Cancer Progression
0 Views •
2021
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors. The mTOR pathway or the...
FAQs
Persistent activation of growth factor receptors can keep intracellular signaling cascades switched on even when normal regulatory control should limit them. The overview specifically identifies RAS-MAPK and PI3K-AKT as examples of cascades involved. Their continued activity helps explain how abnormal molecular communication supports tumor-cell growth and survival rather than only reflecting a temporary response to the surroundings.
Tumor-suppressor signals and programmed cell death provide opposing regulatory pressures within a cell. Mutations or abnormal regulation can weaken these controls while growth and survival signals remain active, allowing tumor cells to persist. Examining both activated pathways and disrupted restraints gives researchers a fuller explanation of tumor development and progression than studying growth signals alone.
Considering RAS-MAPK and PI3K-AKT together broadens analysis beyond a single molecular route. Because cancer-associated abnormalities can affect receptors, intracellular cascades, and regulatory signals, researchers can examine how several parts of the communication network contribute to the same tumor behavior. This wider view is relevant when investigating growth, survival, progression, and treatment resistance.
These studies can connect molecular abnormalities with major tumor behaviors, including uncontrolled growth, continued survival, migration, and responses to surrounding conditions. They also help explain how tumors develop and progress across biological systems. Comparing signaling activity with these outcomes gives biology researchers a framework for relating molecular communication to broader cancer behavior and treatment resistance.
Abnormal receptors, intracellular cascades, or regulatory controls can provide molecular features for investigation as potential biomarkers. Studying these features may help distinguish signaling states associated with tumor development, progression, or treatment resistance. In turn, biomarker research supports more precise cancer diagnosis by connecting measurable molecular information with biologically important tumor characteristics.
Understanding which signaling components remain abnormally active can guide therapies designed to block specific signaling proteins. Research may also examine approaches that restore disrupted regulatory control, including restraints linked to tumor suppressors or programmed cell death. These strategies aim to make treatment more precise by addressing molecular abnormalities connected to tumor growth, survival, or resistance.